Babar Ghias - 17 Dec 2025 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Reporting relationship: Chief Financial Officer
Issuer ticker: BCRX
Reported as of: 17 Dec 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 19 Dec 2025, 16:11:18 UTC
Prior SEC filing: 28 Jul 2025
Source filing: View source filing
Reporting owner signature: /s/ Alane P. Barnes, by power of attorney

Key filing fact

Babar Ghias filed Form 4 for BIOCRYST PHARMACEUTICALS INC (BCRX) on 19 Dec 2025.

Key facts

This page summarizes Babar Ghias's Form 4 filing for BIOCRYST PHARMACEUTICALS INC (BCRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 19 Dec 2025, 16:11.

Change

Previous filing in this sequence was filed on 28 Jul 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002076862 Primary reporting owner

Ghias Babar

Relationship: Chief Financial Officer
Address: 4505 EMPEROR BLVD., SUITE 200, DURHAM
Signature: /s/ Alane P. Barnes, by power of attorney
Signature date: 19 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

BCRX transaction

Common Stock

Award

Transaction value: $0
Shares: +121,700
Change %: +83%
Price: $0.000000
Shares after: 268,700
Date: 17 Dec 2025
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BCRX transaction Derivative

Emp. Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +355,050
Change %
Price: $0.000000
Shares after: 355,050
Date: 17 Dec 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 355,050
Exercise price: $7.13
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Annual award of restricted stock units which will vest 25% on each of the first, second, third and fourth anniversaries of the date of grant.

Footnote F2

Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.